ARC Future Fellowships - Grant ID: FT0991923

Funding Activity

Website
http://dataportal.arc.gov.au/NCGP/Web/Grant/Grant/FT0991923

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Improvement of anthracycline chemotherapy by enhancement of apoptotic responses and tumour targeted activation. Improved outcomes for anthracycline anticancer chemotherapy is of clear benefit to the nation. Tumour-localised treatment is expected to lead to improved responses, reduced side-effects and improved quality of life while rational selection of drug combinations is expected to enable treatment of tumours that were previously resistant to anthracyclines. With an aging population in Australia the incidence of cancer is predicted to rise dramatically - improved treatment outcomes and better use of chemotherapeutics will be of obvious national benefit. The development of new tumour-targeted agents is the subject of joint Intellectual Property between Australia and the USA, offering potential economic benefit.

Funded Activity Details

Start Date: 31-03-2010

End Date: 30-03-2015

Funding Scheme: ARC Future Fellowships

Funding Amount: $686,400.00

Funder: Australian Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Biochemistry: Nucleic Acids | Medical Biochemistry and Metabolomics | Clinical Pharmacology And Therapeutics |

ANZSRC Socio-Economic Objective (SEO)

Cancer and related disorders

Other Keywords

Cancer and related disorders | Clinical Pharmacology And Therapeutics | Medical Biochemistry and Metabolomics | Medical Biochemistry: Nucleic Acids

Related Links